BRCA2 and early-onset autosomal dominant Alzheimer disease: They include disclaimers for consumers to acknowledge prior to release of results, recommend genetic counselling and consumers can exclude specific results, including BRCA1 and BRCA2 and Alzheimer’s Disease.